Outcomes associated with R-CVP vs. R-CHOP.
| Parameter . | Phase III CVP . | Clinical Trial Phase II CHOP . | Phase III CHOP . |
|---|---|---|---|
| Abbrviations: R-CVP, Rituximab + Cyclophosphamide + Vincristine + Prednisone; R-CHOP, Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone; ORR, overall response rate; CR, complete response; TTP, time-to-progression | |||
| * Not reached at median follow-up of 20 months (i.e., 80% of R-CHOP patients still in remission) | |||
| ** Discrepancy between CR rates noted from phase II vs. phase III R-CHOP trials are addressed later in this article and are likely secondary to differences in baseline prognostic factors and patient entry criteria | |||
| ORR | 81% | 100% | 96% |
| % CR | 41% | 87% | 20%** |
| TTP (median) | 32 mos | 82.3 mos | NR* |
| Parameter . | Phase III CVP . | Clinical Trial Phase II CHOP . | Phase III CHOP . |
|---|---|---|---|
| Abbrviations: R-CVP, Rituximab + Cyclophosphamide + Vincristine + Prednisone; R-CHOP, Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone; ORR, overall response rate; CR, complete response; TTP, time-to-progression | |||
| * Not reached at median follow-up of 20 months (i.e., 80% of R-CHOP patients still in remission) | |||
| ** Discrepancy between CR rates noted from phase II vs. phase III R-CHOP trials are addressed later in this article and are likely secondary to differences in baseline prognostic factors and patient entry criteria | |||
| ORR | 81% | 100% | 96% |
| % CR | 41% | 87% | 20%** |
| TTP (median) | 32 mos | 82.3 mos | NR* |